MAP1S

Across TCGA pan-cancer cohorts, MAP1S Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAP1S data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher MAP1S Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAP1S expression acts as an unfavorable survival marker.

DLBC, ACC, and GBM are the cancer types where MAP1S Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	All	0.054	0.842	<.001	12	view →
ACC	DFS	Median	All	0.066	0.667	.002	12	view →
GBM	OS	Median	All	0.151	0.416	.009	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MAP1S–DLBC (OS)

Open the DLBC breakdown →